Addex Therapeutics Short Interest Drops in March

The biopharmaceutical company's stock saw a significant decline in short positions last month.

Apr. 14, 2026 at 5:09am

Got story updates? Submit your updates here. ›

A close-up, high-contrast image of intricate financial machinery and banking equipment, representing the complex mechanics and institutional power of the financial system.The drop in short interest for Addex Therapeutics suggests a shift in investor sentiment, even as the company's stock faces a bearish outlook from one research analyst.Cambridge Today

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) saw a 38.2% drop in short interest in March, with the number of shares shorted falling from 10,913 on March 15 to 6,748 by March 31. The company's stock currently has a short-interest ratio of 1.4 days, with 0.6% of shares short sold.

Why it matters

Short interest data can provide insights into investor sentiment and market expectations around a company's stock. The significant decline in short positions for Addex Therapeutics suggests that some investors may be growing more optimistic about the company's prospects, even as one research analyst maintains a 'sell' rating on the stock.

The details

According to the report, the drop in short interest for Addex Therapeutics occurred during a period when the company's average daily trading volume was 4,754 shares. The current short interest represents 0.6% of the company's outstanding shares.

  • As of March 31, 2026, there was short interest totaling 6,748 shares of Addex Therapeutics.
  • On March 15, 2026, the short interest in Addex Therapeutics was 10,913 shares.

The players

Addex Therapeutics Ltd.

A clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. The company is headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts.

Weiss Ratings

A research firm that recently reiterated a 'sell (e+)' rating on shares of Addex Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

The drop in short interest for Addex Therapeutics suggests that some investors may be growing more optimistic about the company's prospects, even as one research analyst maintains a bearish outlook on the stock. The data provides insight into the market's sentiment around the biopharmaceutical company.